Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease

Página do item simplificado
dc.contributor.authorBrito, Victor Gustavo Balera [UNESP]
dc.contributor.authorPatrocinio, Mariana Sousa [UNESP]
dc.contributor.authorde Sousa, Maria Carolina Linjardi [UNESP]
dc.contributor.authorBarreto, Ayná Emanuelli Alves [UNESP]
dc.contributor.authorFrasnelli, Sabrina Cruz Tfaile [UNESP]
dc.contributor.authorLara, Vanessa Soares
dc.contributor.authorSantos, Carlos Ferreira
dc.contributor.authorOliveira, Sandra Helena Penha [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2021-06-25T11:02:57Z
dc.date.available2021-06-25T11:02:57Z
dc.date.issued2020-11-11
dc.description.abstractPeriodontal disease (PD) is a prevalent inflammatory disease with the most severe consequence being the loss of the alveolar bone and teeth. We therefore aimed to evaluate the effects of telmisartan (TELM), an angiotensin II type 1 receptor (Agtr1) antagonist, on the PD-induced alveolar bone loss, in Wistar (W) and Spontaneous Hypertensive Rats (SHRs). PD was induced by ligating the lower first molars with silk, and 10 mg/kg TELM was concomitantly administered for 15 days. The hemimandibles were subjected to microtomography, ELISA was used for detecting tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), CXCL3, and CCL2, while qRT-PCR was used for analyzing expression of components of renin-angiotensin system (RAS) (Agt, Ace, Agt1r, Agt2r, Ace2, and Masr), and bone markers (Runx2, Osx, Catnb, Alp, Col1a1, Opn, Ocn, Bsp, Bmp2, Trap, Rank, Rankl, CtsK, Mmp-2, Mmp-9, and osteoclast-associated receptor (Oscar)). The SHR + PD group showed greater alveolar bone loss than the W + PD group, what was significantly inhibited by treatment with TELM, especially in the SHR group. Additionally, TELM reduced the production of TNF-α, IL-1β, and CXCL3 in the SHR group. The expression of Agt increased in the groups with PD, while Agtr2 reduced, and TELM reduced the expression of Agtr1 and increased the expression of Agtr2, in W and SHRs. PD did not induce major changes in the expression of bone formation markers, except for the expression of Alp, which decreased in the PD groups. The bone resorption markers expression, Mmp9, Ctsk, and Vtn, was higher in the SHR + PD group, compared to the respective control and W + PD group. However, TELM attenuated these changes and increased the expression of Runx2 and Alp. Our study suggested that TELM has a protective effect on the progression of PD, especially in hypertensive animals, as evaluated by the resorption of the lower alveolar bone. This can be partly explained by the modulation in the expression of Angiotensin II receptors (AT1R and AT2R), reduced production of inflammatory mediators, the reduced expression of resorption markers, and the increased expression of the bone formation markers.en
dc.description.affiliationDepartment of Basic Sciences School of Dentistry São Paulo State University (UNESP)
dc.description.affiliationMulticenter Postgraduate Program in Physiological Sciences Brazilian Society of Physiology School of Dentistry São Paulo State University (UNESP)
dc.description.affiliationDepartment of Stomatology Bauru School of Dentistry University of São Paulo
dc.description.affiliationDepartment of Biological Science Bauru School of Dentistry University of São Paulo
dc.description.affiliationUnespDepartment of Basic Sciences School of Dentistry São Paulo State University (UNESP)
dc.description.affiliationUnespMulticenter Postgraduate Program in Physiological Sciences Brazilian Society of Physiology School of Dentistry São Paulo State University (UNESP)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 2015/03965-2
dc.description.sponsorshipIdFAPESP: 2017/02271-2
dc.description.sponsorshipIdFAPESP: 2017/05873-3
dc.description.sponsorshipIdFAPESP: 2017/07095-8
dc.identifierhttp://dx.doi.org/10.3389/fphar.2020.579926
dc.identifier.citationFrontiers in Pharmacology, v. 11.
dc.identifier.doi10.3389/fphar.2020.579926
dc.identifier.issn1663-9812
dc.identifier.scopus2-s2.0-85096791364
dc.identifier.urihttp://hdl.handle.net/11449/207899
dc.language.isoeng
dc.relation.ispartofFrontiers in Pharmacology
dc.sourceScopus
dc.subjectAT1 blocker
dc.subjectbone metabolism
dc.subjectcytokines
dc.subjectosteobalst
dc.subjectosteoclast
dc.subjectperiodontal disease 4
dc.subjectspontaneous hypertensive rats
dc.subjecttelmisartan
dc.titleTelmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Diseaseen
dc.typeArtigo
unesp.departmentCiências Biológicas - FCpt

Arquivos

Coleções

Bauru - FC - Faculdade de Ciências